Tag: best dentistry award

Seo-Eun Choi | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Dr. Seo-Eun Choi | Medicine and Dentistry | Best Researcher Award

University of Washington, United States

Dr. Seo-Eun Choi is a distinguished Senior Research Scientist at the University of Washington, specializing in statistical applications in biomedical research, particularly Alzheimer’s disease and cognitive studies. She holds a Ph.D. in Statistics from Florida State University, an M.S. in Statistics from the University of Michigan – Ann Arbor, and a B.S. in Statistics with a minor in Computer Science from Ewha Womans University, South Korea. Over her career, Dr. Choi has developed deep expertise in Bayesian modeling, model selection, categorical and multivariate data analysis, spatio-temporal modeling, psychometrics, and neuroimaging data analysis. She has led and contributed to numerous international and interdisciplinary research projects, producing a strong publication record of 96 documents with 728 citations and an h-index of 12, highlighting her influence in both statistical methodology and clinical applications. Her research skills include advanced statistical computing, data visualization, and application of complex statistical models to large-scale neuroimaging and clinical datasets. Dr. Choi is an active member of the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) and the American Statistical Association (ASA), reflecting her engagement with the broader scientific community and commitment to advancing collaborative research initiatives. Her contributions have been recognized through multiple awards and honors for excellence in statistical research, interdisciplinary collaboration, and mentorship, demonstrating her leadership and impact on the field. Looking forward, Dr. Choi’s work has significant potential to advance high-impact publications in Q1 journals, expand global collaborations, and provide mentorship to emerging researchers, thereby influencing both methodological innovation and practical applications in neurodegenerative disease research. Her combination of expertise, experience, and dedication makes her an exemplary candidate for recognition, reflecting outstanding contributions to science, research leadership, and societal impact in the field of biostatistics and neuroscience.

Profile: Google Scholar

Featured Publications

  1. Jutten, R. J., Grandoit, E., Foldi, N. S., Sikkes, S. A. M., Jones, R. N., Choi, S. E., … et al. (2020). Lower practice effects as a marker of cognitive performance and dementia risk: A literature review. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 12(1), 1–12.

  2. Mukherjee, S., Mez, J., Trittschuh, E. H., Saykin, A. J., Gibbons, L. E., Fardo, D. W., … et al. (2020). Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups. Molecular Psychiatry, 25(11), 2942–2951.

  3. Choi, S. E., Mukherjee, S., Gibbons, L. E., Sanders, R. E., Jones, R. N., Tommet, D., … et al. (2020). Development and validation of language and visuospatial composite scores in ADNI. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 6(1), e12024.

  4. Eissman, J. M., Dumitrescu, L., Mahoney, E. R., Smith, A. N., Mukherjee, S., Lee, M. L., … et al. (2022). Sex differences in the genetic architecture of cognitive resilience to Alzheimer’s disease. Brain, 145(7), 2541–2554.

  5. Mukherjee, S., Choi, S. E., Lee, M. L., Scollard, P., Trittschuh, E. H., Mez, J., … et al. (2020). Cognitive domain harmonization and co-calibration in studies of older adults. Neuropsychology, 37(4), 409–423.

Waseem AlZamzami | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Assoc. Prof. Dr. Waseem AlZamzami | Medicine and Dentistry | Best Researcher Award

University of Tabuk, Saudi Arabia

Assoc. Prof. Dr. Waseem A. AlZamzami is an accomplished researcher and academic in hematopathology, molecular hematology, and cancer biology, with a strong focus on genomics, transcriptomics, metabolomics, and bioinformatics. He earned his Ph.D. in Clinical Laboratory Science from The Catholic University of America, Washington DC (2015–2022), following an M.S. in Health Sciences from Quinnipiac University, Connecticut (2013–2015), and a B.Sc. in Laboratory Medicine from Umm Al-Qurra University, Saudi Arabia (2002–2006). His professional journey includes extensive research training at the National Cancer Institute/National Institutes of Health (NCI/NIH), Bethesda, USA, where he contributed to advancing cancer genetics and translational hematology. Currently serving as an Assistant Professor of Hematology at the University of Tabuk, Saudi Arabia, he has held multiple leadership roles such as Committee Chairman for Laboratory Management, Unit Chairman for Measurement and Evaluation, and active member of Accreditation, Quality Assurance, and Curriculum Development committees. His research interests center on genetic screening, biomarker discovery, and integration of multi-omics to drive precision oncology and personalized treatment strategies. Dr. AlZamzami has authored publications in reputed journals including Discovery Medicine, Molecular Syndromology, PLOS ONE, and Cancers, with a Scopus record of 9 documents, 36 citations, and an h-index of 3, alongside three recent Saudi patents in hematological malignancies and cancer genomics. He is also a dedicated reviewer for journals such as PLOS ONE, Process Biochemistry, and International Immunopharmacology. His research skills span molecular diagnostics, bioinformatics, laboratory medicine, multi-omics analysis, and translational applications bridging bench to bedside. Recognized through international symposium presentations at NIH and national scientific forums, he has also contributed to scientific community development by mentoring students and organizing academic events. In conclusion, Dr. Waseem A. AlZamzami exemplifies a distinguished researcher whose academic excellence, innovative research, and leadership contributions to cancer biology and hematology strongly position him as a driving force in advancing precision medicine and biomedical research globally.

Profile: Scopus |ORCID| Google Scholar

Featured Publications

  1. Yan, H., Malik, N., Kim, Y. I., He, Y., Li, M., Dubois, W., Liu, H., Peat, T. J., Nguyen, J. T., … (2021). Fatty acid oxidation is required for embryonic stem cell survival during metabolic stress. EMBO Reports, 22(6), e52122.

  2. Oyouni, A. A. A., Al-Amer, O. M., Ali, F. A. Z., Altayar, M. A., Jalal, M. M., Albalawi, R. S. M., … (2022). Melatonin ameliorates the adrenal and pancreatic alterations in streptozotocin-induced diabetic rats: Clinical, biochemical, and descriptive histopathological studies. Frontiers in Veterinary Science, 9, 1016312.

  3. Seshadri, V. D., Oyouni, A. A. A., Hawsawi, Y. M., Aljohani, S. A. S., Al-Amer, O. M., … (2022). Chemopreventive role of Tin oxide–Chitosan–Polyethylene glycol–Crocin nanocomposites against lung cancer: An in vitro and in vivo approach. Process Biochemistry, 120, 186–194.

  4. Al-Amer, O. M., Mir, R., Hamadi, A., Alasseiri, M. I., Altayar, M. A., AlZamzami, W., … (2023). Antiapoptotic gene genotype and allele variations and the risk of lymphoma. Cancers, 15(4), 1012.

  5. Vijayaragavan, P., Rathi, M. A., Gopalakrishnan, V. K., Pashameah, R. A., … (2022). CpG methylation analysis of tumour suppressor gene and expression of cathepsin B in renal cell carcinoma. Journal of King Saud University – Science, 34(8), 102330.

Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Dr. Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Mary Bird Perkins Cancer Center | United States

Dr. Sotirios Stathakis is an accomplished medical physicist with extensive experience in radiation oncology, advanced treatment planning, and patient safety in cancer care. Currently serving as the Chief of Physics at Mary Bird Perkins Cancer Center and Adjunct Professor at Louisiana State University, he has established himself as a leader in both clinical and academic domains. His work bridges fundamental research and real-world clinical application, focusing on improving the accuracy, efficiency, and safety of radiotherapy treatments. With a career spanning over two decades, Dr. Stathakis has played a pivotal role in advancing technologies such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), Monte Carlo simulations, and adaptive radiotherapy. He has supervised graduate students, medical residents, and postdoctoral fellows, contributing to the development of the next generation of medical physicists. Dr. Stathakis is internationally recognized for his innovative contributions to medical physics, publishing widely in peer-reviewed journals and presenting at global conferences. His leadership in quality assurance (QA) protocols, radiotherapy safety standards, and patient-centered innovations has earned him professional recognition as a Fellow of the American Association of Physicists in Medicine (AAPM). He continues to expand his research by integrating artificial intelligence, patient education, and wearable technology into cancer care.

Professional Profile

Scopus | ORCID

Education

Dr. Sotirios Stathakis has a strong academic background rooted in physics and medical physics, which forms the foundation of his distinguished career in cancer treatment and research. He began his academic journey with a Bachelor of Science in Physics from the University of Waterloo, Canada, where he developed a strong foundation in core physical sciences and problem-solving skills. Driven by an interest in applying physics to medicine, he pursued a Master of Science in Medical Physics at the University of Aberdeen, United Kingdom. Here, he received specialized training in radiological sciences, medical imaging, and radiotherapy applications, which fueled his passion for research in patient care. His academic progression culminated in a Ph.D. in Medical Physics from the University of Patras, Greece, where his doctoral work focused on advanced radiation dosimetry and optimization of treatment planning systems. His doctoral training allowed him to explore Monte Carlo simulations and radiation safety protocols, which later became key aspects of his professional contributions. This comprehensive education, spanning North America and Europe, equipped him with a unique global perspective and multidisciplinary expertise. It also prepared him to integrate clinical practice with research, ultimately shaping his career as a recognized leader in medical physics and radiation oncology.

Professional Experience

Dr. Sotirios Stathakis has accumulated diverse professional experience that reflects his dual commitment to academic research and clinical application. He began his career in Europe, contributing to medical physics research before moving to the United States, where he established himself in leading academic and clinical institutions. At the University of Texas Health Science Center San Antonio (UTHSA), he served as a Professor and Medical Physicist, taking on responsibilities that included treatment planning, clinical implementation of new radiotherapy techniques, and the supervision of graduate students and medical residents. His academic contributions included teaching advanced courses in radiation oncology physics and mentoring Ph.D. dissertations. He later transitioned to his current role as Chief of Physics at Mary Bird Perkins Cancer Center, where he oversees medical physics operations across multiple oncology centers. In this role, he leads a team of physicists and ensures the safe and effective delivery of radiation treatments to cancer patients. His position as Adjunct Professor at Louisiana State University complements his clinical work, as he continues to teach and mentor the next generation of medical physicists. Throughout his career, Dr. Stathakis has balanced leadership, clinical service, and research, contributing to advancements in both patient care and academic knowledge.

Research Interests

Dr. Sotirios Stathakis’s research interests lie at the intersection of clinical innovation, radiation therapy optimization, and patient-centered approaches. A central focus of his research is the improvement of treatment planning systems, particularly through advanced modeling such as Monte Carlo simulations, which enhance accuracy in dose calculations. He has contributed to the development and refinement of quality assurance (QA) protocols, ensuring precision in intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). Another important area of his research includes studying the secondary cancer risks associated with radiotherapy, providing valuable insights into long-term patient safety. Dr. Stathakis is also exploring the role of artificial intelligence (AI) in radiotherapy, particularly for dose prediction and workflow optimization, which has the potential to revolutionize clinical practices. In recent years, he has expanded his focus to include patient-centered technologies, such as wearable monitoring devices and virtual reality tools that improve patient education, engagement, and treatment compliance. His interdisciplinary approach combines physics, engineering, computer science, and clinical oncology, creating innovative solutions to complex healthcare challenges. By bridging these fields, Dr. Stathakis continues to advance the standards of radiotherapy, contributing to safer, more effective, and personalized cancer treatments.

Research Skills

Dr. Sotirios Stathakis possesses a broad range of research skills that span computational modeling, experimental validation, clinical trial design, and academic mentoring. His expertise in Monte Carlo simulations allows him to perform highly accurate radiation dose calculations, a critical aspect of treatment planning and safety assessment in radiation oncology. He is also highly skilled in advanced quality assurance techniques, particularly for IMRT and VMAT, ensuring reliable and precise delivery of radiation therapy. Dr. Stathakis is proficient in using and commissioning treatment planning systems and linear accelerators, applying both theoretical and practical approaches to improve clinical workflows. His research methodology incorporates statistical analysis, machine learning, and artificial intelligence, enabling him to address complex problems in treatment optimization and patient safety. Beyond technical skills, he excels in collaborative project management, coordinating interdisciplinary teams across physics, medicine, and engineering. His experience extends to academic publishing, peer review, and conference presentations, reflecting his ability to effectively disseminate scientific findings. As a mentor and educator, he has guided Ph.D. students and medical residents in developing independent research projects, further demonstrating his leadership in research environments. Collectively, these skills highlight his ability to translate advanced scientific concepts into practical innovations that benefit cancer patients worldwide.

Awards and Honors

Throughout his career, Dr. Sotirios Stathakis has received numerous awards and honors in recognition of his academic excellence, clinical leadership, and professional service. One of the most prestigious distinctions in his career is being named a Fellow of the American Association of Physicists in Medicine (AAPM), a recognition reserved for members who have made significant contributions to the advancement of medical physics. He is also board-certified in Therapeutic Radiologic Physics by the American Board of Radiology (ABR), underscoring his professional expertise and credibility in clinical practice. His academic work has been acknowledged through invitations to present at leading international conferences, including those organized by IEEE, AAPM, and ESTRO, where he has shared groundbreaking findings on radiotherapy optimization and quality assurance. In addition, Dr. Stathakis has served as a peer reviewer for high-impact journals such as the Journal of Applied Clinical Medical Physics (JACMP), further highlighting his standing in the scientific community. He has also been recognized by institutions where he has taught and worked, receiving commendations for excellence in mentorship and clinical service. These honors reflect his consistent commitment to innovation, patient safety, and education, solidifying his reputation as a respected leader in medical physics and radiation oncology.

Publication Top Notes

  • AAPM TG report 312: Acceptance testing, commissioning, and periodic quality assurance of ion chamber and diode detector arrays — 2025

  • Dosimetric characterization of a new surface-conforming electron MLC prototype — 2024 — 1 citation

  • Monte Carlo modeling of the Elekta Versa HD and patient dose calculation with EGSnrc/BEAMnrc — 2022 — 5 citations

  • Erratum to: Report of AAPM Task Group 219 on independent calculation-based dose/MU verification for IMRT — 2021

  • Artificial intelligence based deconvolving on megavoltage photon beam profiles for radiotherapy applications — 2022

  • A customizable aluminum compensator system for total body irradiation — 2021

Conclusion

Dr. Sotirios Stathakis’s career represents a remarkable combination of academic excellence, clinical innovation, and professional leadership. His work has transformed multiple aspects of radiation oncology, from enhancing treatment planning accuracy to implementing robust quality assurance protocols that safeguard patient outcomes. With a strong foundation in education from top institutions across Canada, the United Kingdom, and Greece, coupled with his leadership roles in the United States, he exemplifies the global nature of medical physics. His research interests and skills reflect both scientific rigor and compassion, as he continually integrates patient-centered approaches into his innovations. Recognized internationally through awards, honors, and professional certifications, Dr. Stathakis has established himself as a trusted authority in his field. His mentorship of students and collaboration with clinicians ensure that his influence extends beyond his individual achievements, shaping the future of cancer care. Looking ahead, his engagement with artificial intelligence, wearable technology, and advanced radiotherapy models positions him to make further groundbreaking contributions. In sum, Dr. Stathakis embodies the qualities of a dedicated researcher, educator, and clinician, making him not only a leader in medical physics but also a driving force in advancing the fight against cancer globally.

Hau Xuan Nguyen | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Assist. Prof. Dr. Hau Xuan Nguyen | Medicine and Dentistry | Best Researcher Award

Hanoi Medical University | Vietnam

Assist. Prof. Dr. Hau Xuan Nguyen is a renowned oncologist and surgical innovator from Vietnam, currently serving as Vice Director of the Oncology Center at Hanoi Medical University Hospital and Associate Professor of Medicine at Hanoi Medical University. With over a decade of experience in oncology and surgical oncology, he has made pioneering contributions to cancer diagnosis and treatment, particularly in head, neck, thyroid, and breast cancers. Assist. Prof. Dr. Hau Xuan Nguyen has significantly advanced minimally invasive surgical techniques, notably the transoral endoscopic thyroidectomy vestibular approach (TOETVA), which has improved patient outcomes and reduced post-surgical complications. His expertise spans clinical oncology, surgical oncology, and palliative care, making him a multifaceted leader in both academic and clinical domains. In addition to his clinical roles, he is an accomplished researcher and educator, having published extensively in national and international journals indexed in Scopus, PubMed, and Web of Science. Assist. Prof. Dr. Hau Xuan Nguyen has co-authored over 80 peer-reviewed articles and several influential medical textbooks, contributing to the academic growth of oncology in Vietnam. His research has gained international recognition through collaborations with leading institutions in Ireland, South Korea, and Japan. Assist. Prof. Dr. Hau Xuan Nguyen dedication to patient care, medical research, and surgical innovation underscores his role as a driving force in global oncology.

Professional Profile

Scopus

Education

Assist. Prof. Dr. Hau Xuan Nguyen academic journey reflects a steady progression of excellence and commitment to oncology and surgical innovation. He began his medical career at Hanoi Medical University, where he earned his degree as a General Practitioner. His keen interest in oncology led him to pursue residency training in Oncology at the same institution, equipping him with strong foundations in cancer management. He later advanced his training internationally, undertaking a surgical oncology fellowship at Beaumont Hospital, Royal College of Surgeons in Ireland, where he gained exposure to global practices in cancer surgery. Further strengthening his expertise, he completed another fellowship at the Thyroid Cancer Center, Yonsei University Hospital, South Korea, specializing in innovative thyroid cancer treatments. Assist. Prof. Dr. Hau Xuan Nguyen pursued his Ph.D. in Oncology at Hanoi Medical University, during which he developed expertise in cancer biology, surgical techniques, and clinical research. He achieved the distinguished title of Associate Professor of Medicine in Oncology, affirming his academic leadership. His comprehensive education, both domestic and international, has provided him with a unique blend of clinical excellence, research capability, and surgical innovation, preparing him to serve as a leader in oncology in Vietnam and globally.

Professional Experience

Over the course of his career, Assist. Prof. Dr. Hau Xuan Nguyen has held multiple academic and clinical positions that highlight his leadership and expertise in oncology. he has served as a Lecturer at the Department of Oncology, Hanoi Medical University, where he has trained and mentored the next generation of oncologists. His dedication to clinical practice is evident in his role as a Surgeon at the Department of Oncology and Palliative Care, Hanoi Medical University Hospital, where he provides direct care to cancer patients with complex conditions. Assist. Prof. Dr. Hau Xuan Nguyen was appointed Vice Director of the Oncology Center at Hanoi Medical University Hospital, a prestigious leadership role where he oversees cancer treatment strategies, clinical innovations, and patient care management. Alongside his teaching and clinical responsibilities, he has played a key role in developing advanced surgical practices in Vietnam, particularly in minimally invasive cancer surgery. His leadership extends beyond clinical practice, as he has contributed significantly to academic publishing, national cancer treatment guidelines, and research collaborations. Through his multifaceted professional career, Assist. Prof. Dr. Hau Xuan Nguyen has established himself as a leading figure in oncology, balancing patient care, surgical innovation, teaching, and global research collaborations.

Research Interests

Assist. Prof. Dr. Hau Xuan Nguyen research interests lie at the intersection of surgical oncology, cancer diagnosis, and innovative treatment approaches. His primary focus is on thyroid cancer, head and neck cancers, breast cancer, and gastrointestinal malignancies, where he explores advanced surgical interventions and minimally invasive procedures to improve treatment outcomes. One of his notable areas of expertise is the transoral endoscopic thyroidectomy vestibular approach (TOETVA), a pioneering surgical technique that offers a scar-free solution and reduces post-operative morbidity. He has also conducted extensive research on sentinel lymph node biopsy in thyroid carcinoma, contributing valuable findings to the improvement of surgical staging and treatment planning in oncology. Beyond surgery, Assist. Prof. Dr. Hau Xuan Nguyen is interested in multidisciplinary cancer care, integrating surgery, chemotherapy, targeted therapies, and palliative care to achieve holistic patient management. His publications also reflect a strong commitment to clinical trials, case reports, and molecular studies that provide insights into genetic mutations and their role in cancer progression. Additionally, he has collaborated internationally on studies involving endoscopic and robotic surgical techniques. Through these research interests, Assist. Prof. Dr. Hau Xuan Nguyen is shaping both clinical practice and academic discourse in oncology, with a vision of advancing precision medicine and minimally invasive cancer treatment worldwide.

Research Skills

Assist. Prof. Dr. Hau Xuan Nguyen possesses a comprehensive set of research skills that combine clinical expertise with rigorous scientific methodology. He is highly skilled in designing and conducting clinical trials, particularly those assessing surgical techniques and oncological outcomes. His expertise in endoscopic and minimally invasive surgery has allowed him to contribute to international literature on advanced surgical oncology, with publications in high-impact journals such as Surgical Endoscopy, Oral Oncology, and Journal of Thyroid Research. Assist. Prof. Dr. Hau Xuan Nguyen has strong proficiency in oncological pathology analysis, molecular diagnostics, and cancer genetics, demonstrated by his work on identifying genetic mutations related to breast, thyroid, and colorectal cancers. His ability to use advanced surgical techniques, including robotic and transoral procedures, underscores his practical research contributions. In addition, he has authored six textbooks on oncology and cancer surgery, reflecting his ability to translate research into academic resources for students and practitioners. He also has extensive experience in academic publishing, peer review, and mentoring early-career researchers in oncology. His research skills are further strengthened by collaborations with international partners, where he has applied evidence-based approaches and contributed to comparative surgical studies. Overall, his diverse research competencies make him a global contributor to oncology innovation and academic development.

Awards and Honors

Assist. Prof. Dr. Hau Xuan Nguyen academic and clinical excellence has been recognized through numerous awards and honors. Notably, he received the Best Certificate at the Congress of the Asia Pacific Society of Thyroid Surgery in Japan for his outstanding research on the role of sentinel lymph node biopsy in thyroid carcinoma. His contributions to cancer surgery and research have also been acknowledged nationally through multiple awards for excellence in surgical oncology and publications in Vietnamese medical journals. He has co-authored influential oncology textbooks such as Oncology, Head and Neck Cancer, Thyroid Cancer, and Atlas of Thyroid Surgery, which are widely used by medical professionals and students in Vietnam. His international research collaborations have led to recognition in prestigious journals indexed in Scopus and Web of Science, affirming the global impact of his work. Additionally, his promotion to Associate Professor of Medicine represents a major academic honor, acknowledging his leadership in teaching, research, and clinical practice. Through these accolades, Assist. Prof. Dr. Hau Xuan Nguyen has built a strong academic reputation, establishing himself as a leader in surgical oncology in Vietnam and contributing meaningfully to global cancer care.

Publication Top Notes

  • Evaluate treatment results of stage II bladder cancer treatment with partial bladder surgery in National Cancer Hospital — 2014

  • Clinical features of stage III-IV tongue cancers treated by chemotherapy pre-surgery and/or radiotherapy — 2014

  • Evaluating the results of surgery for thyroid cancer at Hanoi Medical University Hospital — 2015

  • Evaluate the role of needle biopsy in the diagnosis of lung cancer before treatment — 2014

  • Evaluating the results of endoscopic surgery for benign thyroid at Hanoi Medical University Hospital — 2015

  • Evaluation of the results of the combination regimen of Gemcitabine with Cisplatin for the treatment of stage IV non-small-cell lung cancer — 2015

  • The results of the sentinel lymph node biopsy by methylene blue in thyroid cancer — 2017

Conclusion

Assist. Prof. Dr. Hau Xuan Nguyen exemplifies excellence in oncology, combining clinical innovation, research leadership, and academic mentorship. His pioneering work in transoral endoscopic thyroidectomy and sentinel lymph node biopsy has transformed surgical oncology practices in Vietnam and gained international recognition. With over 80 national and international publications, several oncology textbooks, and leadership roles in both academia and clinical care, he has significantly advanced the standards of cancer treatment and education. His strong research background, global collaborations, and focus on minimally invasive cancer therapies position him as a leader in the future of oncology. Beyond his academic achievements, his dedication to patient care and commitment to training the next generation of oncologists demonstrate his holistic approach to advancing medical science and society. Assist. Prof. Dr. Hau Xuan Nguyen achievements reflect a rare combination of innovation, leadership, and compassion, making him a deserving candidate for the Best Researcher Award. His future research will likely continue to push the boundaries of surgical oncology, enhancing cancer treatment outcomes not only in Vietnam but across the global medical community.

Maria Kourti | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Prof. Maria Kourti | Medicine and Dentistry | Best Researcher Award

Aristotle University of Thessaloniki | Greece

Prof. Maria Kourti is a distinguished academic and medical professional specializing in Pediatrics with a particular focus on Pediatric Hematology, Oncology, and Infectious Diseases. She currently serves as an Assistant Professor at Aristotle University of Thessaloniki, where she has been deeply involved in both teaching and research. Her career spans over two decades of excellence in clinical practice, scientific research, and international collaborations, with significant contributions to the understanding of childhood leukemia, drug resistance mechanisms, and pediatric infectious diseases. She has authored 73 publications indexed in PubMed, holds an h-index of 16, and has received over 1,000 citations, making her a recognized figure in her field. Prof. Kourti has combined clinical expertise with cutting-edge molecular and proteomic research, actively leading and participating in international multicenter studies and clinical trials. She is also extensively engaged in professional societies at the European and global levels, serving as a board member and committee leader in organizations dedicated to pediatric health. Alongside her academic achievements, she has contributed to medical education, mentorship, and health promotion initiatives, underlining her holistic approach to advancing both science and society. Her distinguished record makes her a highly respected leader in pediatric research and medicine.

Professional Profile

Scopus | ORCID 

Education

Prof. Maria Kourti pursued her entire academic journey at the Aristotle University of Thessaloniki, Greece, one of the most prestigious institutions in the country. She obtained her Medical Degree, laying the foundation for her career in pediatrics. With a strong interest in scientific research, she further advanced her education by earning a Master of Science (MSc) in Medical Research Technology, where she developed early expertise in biomedical investigations. Her passion for oncology and molecular medicine culminated in her Ph.D, with her thesis focused on the “Study of expression of multi-drug resistance genes in pediatric leukemia,” a topic that remains central to her research today. Her commitment to academic and clinical growth did not stop there, as she pursued advanced medical specialization, becoming Board Certified as a Specialist Pediatrician and later recognized as a Pediatric Infectious Disease Specialist. In the same year, she also completed a Post-Doctoral Fellowship in Proteomics in Childhood Leukemia, marking her continued dedication to translational research. This progression highlights her unique integration of medicine and science, equipping her with the academic depth and clinical expertise to make pioneering contributions in pediatric hematology, oncology, and infectious diseases.

Professional Experience

Prof. Maria Kourti has held several critical roles in clinical practice and academia, reflecting her dual expertise as a physician and researcher. she served as an Attending Physician in the Pediatric Oncology Department at Hippokration General Hospital, where she gained extensive clinical experience in treating children with hematological malignancies and solid tumors. Her expertise further deepened during her Pediatric Infectious Disease Fellowship at Aristotle University of Thessaloniki, based at Hippokration General Hospital. she worked as an Attending Physician in the 3rd Department of Pediatrics at Aristotle University, responsible for managing the Pediatric Hematology Unit, demonstrating her leadership in both patient care and academic responsibilities. she was appointed Assistant Professor of Pediatrics–Pediatric Hematology and Oncology at Aristotle University of Thessaloniki, where she continues to combine clinical duties with teaching and high-level research. Her responsibilities extend beyond the university, as she actively participates in national and international research programs, leading initiatives on childhood cancer, supportive care, and clinical trials. Through these roles, Prof. Kourti has developed a reputation for clinical excellence, academic leadership, and research innovation, making her a central figure in pediatric hematology and oncology in Greece and abroad.

Research Interests

Prof. Kourti’s research interests span the intersection of molecular biology, pediatric oncology, and infectious diseases, with a strong emphasis on improving treatment outcomes for children with cancer. Her doctoral and postdoctoral work centered on the molecular mechanisms of drug resistance in childhood leukemia, specifically the expression of multi-drug resistance genes and the application of proteomics to understand disease progression and treatment response. She has also been deeply engaged in genetic polymorphism studies, particularly in metabolic enzymes of carcinogenic substances in patients with acute leukemias and myelodysplastic syndromes. In addition to her oncology work, she has pursued significant research in pediatric infectious diseases, coordinating national efforts for the Greek Supportive Care Group and contributing to clinical research on antifungal therapies and novel antimicrobial strategies. Her interests also extend to large-scale clinical collaborations, where she has been both principal and sub-investigator in 15 multinational clinical trials addressing treatments for pediatric cancers and infections. This breadth of research demonstrates her commitment to translational medicine, bridging laboratory research with clinical applications. Her interests align with global health priorities, focusing on improving survival, reducing treatment toxicity, and enhancing supportive care in children with cancer.

Research Skills

Prof. Kourti possesses a strong foundation in molecular biology and clinical research methodologies, supported by advanced training and decades of practical application. Her technical expertise includes DNA and RNA extraction from blood and bone marrow samples, agarose gel electrophoresis, PCR, and RT-PCR, enabling her to investigate genetic and proteomic markers in pediatric leukemia. She has extensive experience with clinical trial design and implementation, having served as both a principal investigator and sub-investigator in numerous international studies, particularly within the SIOPE and SIOPEN networks. Her skills also extend to multidisciplinary collaboration, coordinating research teams across clinical and laboratory settings. In addition, Prof. Kourti has developed editorial and peer-review skills through her role as Guest Editor of special issues in international journals such as the Journal of Fungi and Diagnostics and as a reviewer for more than 10 medical journals. She also demonstrates expertise in data interpretation, publication writing, and conference presentation, with over 100 oral and poster presentations at national and international congresses. Her combined clinical and laboratory research skills, along with her organizational and editorial experience, make her a versatile and influential contributor to pediatric oncology and infectious disease research worldwide.

Awards and Honors

Throughout her career, Prof. Maria Kourti has received numerous awards and honors recognizing her excellence in research, teaching, and clinical practice. She has earned 10 major distinctions, including 3 scholarships from the National Scholarship Foundation (IKY), awarded for her academic performance and research potential. In addition, she has received 3 educational grants supporting her clinical and research training, as well as 6 first prizes for oral and poster presentations at both national and international medical congresses. These awards highlight not only her dedication to scientific inquiry but also her ability to effectively communicate her findings to diverse audiences. Beyond individual recognition, her leadership roles within professional societies such as the Hellenic Society for Social Pediatrics and Health Promotion, the National Pediatric Hematology and Oncology Society, and participation in European cooperative groups (SIOPE, ESPID, EXPeRT, ESCMID) further demonstrate the esteem in which she is held by the medical and scientific community. She has also contributed as a committee member for sustainability at ESPID, reflecting her commitment to long-term scientific advancement and ethical research practices. These honors collectively underscore her outstanding achievements and her influential role in pediatric medicine and research.

Publication Top Notes

  • Antifungal Use in Immunocompromised Children in Europe: A 12-Week Multicenter Weekly Point Prevalence Survey (CALYPSO) — 2025

  • A Global Analysis of Cases of Mucormycosis Recorded in the ECMM / ISHAM Zygomyco.net Registry from 2009 to 2022 — 2025

  • Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Research Network — 2025 — 3 citations

  • Addressing infectious challenges in pediatric cancer and hematopoietic cell transplantation: insights from the Umbrella Working Group — 2025

  • Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients — 2025

  • Planetary Health: What You Need to Know as a Pediatric Infectious Diseases Doctor — 2025

  • Successful Treatment of Disseminated Fusariosis in a 15-Month-old Boy With Refractory Acute Lymphoblastic Leukemia Using High-dose Voriconazole — 2024 — 1 citation

  • Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps — 2025

Conclusion

Prof. Maria Kourti exemplifies the qualities of a leading physician-scientist, with a career that integrates clinical expertise, innovative research, and academic leadership. Her groundbreaking work in childhood leukemia, infectious diseases, and pediatric oncology has advanced both scientific knowledge and clinical practice, directly impacting patient outcomes. With more than 73 peer-reviewed publications, extensive participation in international clinical trials, and leadership in national and European research groups, she has established herself as a key figure in the global pediatric research community. Her commitment to mentoring young scientists, active involvement in health promotion initiatives, and editorial contributions further enhance her academic profile. Looking ahead, Prof. Kourti is well-positioned to expand her research into global collaborations, increase her presence in high-impact journals, and take on greater leadership roles in shaping international pediatric oncology policies. Her career trajectory reflects not only past accomplishments but also significant potential for future contributions to medicine, making her a highly deserving candidate for continued recognition. In summary, Prof. Kourti’s lifelong dedication to advancing pediatric care and medical science positions her as an outstanding role model and leader in the field.

Nobuhiro Takahashi | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Dr. Nobuhiro Takahashi | Medicine and Dentistry | Best Researcher Award

Dermatologist from Tokai University School of Medicine, Japan

Dr. Nobuhiro Takahashi is a dedicated clinical professional specializing in dermatology, with a primary focus on inflammatory skin diseases. Currently serving as a Clinical Assistant in the Department of Dermatology at Tokai University Hospital, Kanagawa, Japan, Dr. Takahashi actively participates in both clinical practice and academic training. He has demonstrated a strong commitment to advancing patient care in outpatient dermatology. His work reflects a growing interest in combining clinical insights with research opportunities. With a solid foundation in medical education and practical experience, Dr. Takahashi shows promise for contributing significantly to dermatological research in the future.

Professional Profile

Education

Dr. Nobuhiro Takahashi completed his medical degree at Tokai University School of Medicine, Japan, graduating in March 2020. His academic training provided him with a comprehensive understanding of medical sciences, with a particular interest in dermatology developing during his studies. The rigorous curriculum at Tokai University laid the groundwork for his clinical reasoning, diagnostic skills, and patient management techniques. His education emphasized both theoretical knowledge and practical application, preparing him effectively for postgraduate clinical training and his current clinical role. Dr. Takahashi’s education continues to support his professional development and potential future contributions to clinical research.

Professional Experience

Dr. Takahashi began his professional journey as a Clinical Resident at Tokai University Hospital, where he completed a two-year postgraduate clinical training program from April 2020 to March 2022. This experience allowed him to build strong diagnostic and treatment skills across multiple medical disciplines. Since April 2022, he has been serving as a Clinical Assistant in the Department of Dermatology at Tokai University. In this role, he focuses on outpatient clinical dermatology and academic training, working closely with specialists to manage a variety of dermatological conditions. His current responsibilities allow him to blend clinical service with ongoing professional growth.

Research Interest

Dr. Takahashi’s primary research interests center around dermatology, particularly the study and management of inflammatory skin diseases. He is focused on improving clinical outcomes and advancing therapeutic strategies for these complex skin conditions. His exposure to diverse patient cases in an outpatient setting provides valuable clinical observations that can guide his research direction. While his current profile does not extensively detail research projects or publications, his interest in bridging clinical practice with academic research is evident. Dr. Takahashi is well-positioned to contribute to future dermatological studies that address common and challenging skin disorders.

Research Skills

Dr. Takahashi has developed a strong set of clinical and observational skills through his extensive outpatient dermatology practice. His ability to diagnose, monitor, and manage various skin conditions equips him with firsthand clinical insights essential for relevant and impactful research. Although specific laboratory or advanced research techniques are not detailed in his profile, his clinical experience supports potential development in clinical research methodologies, case study analysis, and patient-centered research. His ongoing academic training is expected to enhance his research capabilities further, enabling him to contribute to clinical trials and evidence-based dermatology studies.

Award and Honors

At this stage of his career, Dr. Takahashi has not yet received formal awards or honors in the field of dermatology or medical research. His professional achievements thus far reflect his dedication to clinical practice and academic growth. As he continues to develop his research portfolio and engage in scholarly activities, there is significant potential for him to earn recognition in the future. Participation in conferences, collaborative research, and contributions to peer-reviewed publications will likely pave the way for future awards and academic honors that acknowledge his efforts in advancing dermatological science.

Conclusion

In conclusion, Dr. Nobuhiro Takahashi is an emerging clinical dermatologist with a promising future in research. His solid educational background, hands-on clinical experience, and keen interest in inflammatory skin diseases demonstrate his dedication to the field. Although he currently has limited research output and formal recognitions, his trajectory indicates potential for future contributions to dermatological science. With continued clinical engagement, research involvement, and academic participation, Dr. Takahashi can develop into a respected researcher who significantly impacts both patient care and dermatological research. His career is well-positioned for continued growth and achievement.

Publication Top Note

  1. Title: A Case of Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
  • Journal: JEADV Clinical Practice
  • Year: 2025

 

Xia Chen | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Ms. Xia Chen | Medicine and Dentistry |  Best Researcher Award

Professor from Yunnan Provincial Hospital of Chinese Medicine, China

Xia Chen is an accomplished chief physician, professor, and master’s supervisor, specializing in integrated Chinese and Western medicine, particularly in gastroenterology. Born in 1978 in Yunnan, China, she has devoted more than two decades to clinical practice, teaching, and scientific research. Currently, she serves as the leader of the Department of Gastroenterology of Traditional Chinese Medicine at Yunnan Provincial Hospital of Chinese Medicine. She has gained recognition as an Outstanding Young Practitioner of Chinese Medicine in Yunnan Province and holds membership in the Hepatobiliary Disease Branch of the Chinese Medical Association. Her career focuses on the diagnosis and treatment of digestive diseases using both traditional Chinese medicine and Western medicine approaches. Xia Chen’s contribution extends beyond clinical work to research projects, drug trials, and academic publishing. Her ability to bridge traditional and modern medical practices has made her a notable figure in her field. Over the years, she has led and participated in numerous prestigious research projects and has authored or co-authored several scholarly works. Xia Chen’s career reflects dedication to improving healthcare outcomes through integrated medicine and advancing research in digestive health, making her a leader in her specialty and an inspiration for future researchers and clinicians.

Professional Profile

Education

Although detailed information about Xia Chen’s educational background is not explicitly provided, her current standing as a chief physician and professor suggests a comprehensive academic journey in medicine, likely beginning with a bachelor’s degree in traditional Chinese medicine or clinical medicine. Following her undergraduate studies, it is plausible she pursued further specialization, completing advanced degrees, possibly a master’s degree or doctorate, focusing on integrated Chinese and Western medicine with a specialty in digestive diseases. Xia Chen’s position as a master’s supervisor also indicates her formal academic qualification aligns with national standards for academic leadership roles in China, which typically require at least a master’s degree combined with significant clinical expertise. Her education would have provided her a strong foundation in traditional Chinese medical principles, combined with extensive training in modern clinical practices, pharmacology, and research methodology. Given her leadership in research projects and teaching, she likely continued her professional development through certifications, clinical fellowships, and continuous medical education programs. Her educational journey underpins her expertise in gastroenterology and serves as the backbone for her clinical, academic, and research excellence.

Professional Experience

Xia Chen has built a remarkable professional career, accumulating over 20 years of experience in clinical practice, teaching, and research in the field of integrated Chinese and Western medicine. She currently serves as the leader of the Department of Gastroenterology of Traditional Chinese Medicine at Yunnan Provincial Hospital of Chinese Medicine. Her daily responsibilities include diagnosing and treating patients with complex digestive diseases, mentoring master’s students, and overseeing research activities. She has established herself as a specialist who skillfully combines traditional Chinese medical therapies with modern Western treatments, offering holistic and effective patient care. Xia Chen’s leadership extends to supervising clinical trials and participating in national Phase II, III, and IV drug research studies. Her practical skills are complemented by her academic contributions, which include teaching future healthcare professionals and guiding research initiatives. Furthermore, she actively contributes to healthcare policy improvements through her roles in professional associations such as the Hepatobiliary Disease Branch of the Chinese Medical Association. Her professional experience highlights her comprehensive expertise across clinical, academic, and scientific domains, making her a pivotal figure in advancing the integration of traditional Chinese medicine with contemporary medical science.

Research Interests

Xia Chen’s research interests focus on the integration of traditional Chinese medicine and Western medicine approaches to digestive diseases. A significant part of her work explores the therapeutic effects of natural medicines on intestinal dynamics. Her research aims to scientifically validate the efficacy of traditional remedies and their mechanisms of action, thereby bridging the gap between ancient practices and modern clinical science. Additionally, Xia Chen is deeply interested in clinical trials related to new drug developments, having participated in numerous national Phase II, III, and IV studies. Her research spans studying gastrointestinal motility disorders, chronic digestive conditions, and hepatobiliary diseases. She is particularly motivated by the desire to develop more effective, less invasive, and side-effect-minimized treatments through integrative approaches. Another important research area for Xia Chen is understanding how traditional Chinese formulations can complement or enhance the effects of Western pharmacological interventions. Her research is highly practical, patient-centered, and innovative, targeting improvements in clinical outcomes. With a growing emphasis on evidence-based medicine, her work contributes significantly to validating and modernizing traditional Chinese medicinal practices while maintaining their historical integrity and therapeutic richness.

Research Skills

Xia Chen possesses a broad range of research skills that have been instrumental in her professional success. She demonstrates expertise in designing and conducting clinical trials, especially those combining traditional Chinese medicinal approaches with Western methodologies. Her skill set includes protocol development, patient recruitment and management, data analysis, and reporting in accordance with national and international standards. She is proficient in evaluating the pharmacological effects of natural medicines and their applications in digestive health. Xia Chen’s publication record highlights her ability to carry out longitudinal studies and synthesize findings for publication in peer-reviewed journals. Her role as a master’s supervisor also reflects her ability to guide young researchers in research design, methodology, and thesis writing. Furthermore, her participation in over ten national drug studies indicates advanced skills in regulatory compliance, clinical pharmacology, and interdisciplinary collaboration. Xia Chen’s integrated approach to traditional and modern research paradigms exemplifies her unique strengths. Her research methodology is thorough, combining qualitative insights from traditional Chinese medicine with the quantitative rigor required in modern clinical research. These combined skills make her a formidable researcher capable of making impactful contributions to the field.

Awards and Honors

Throughout her distinguished career, Xia Chen has received notable awards and honors recognizing her professional and academic contributions. She has been named an Outstanding Young Practitioner of Chinese Medicine in Yunnan Province, an accolade that underscores her clinical excellence, research innovation, and contributions to the advancement of traditional Chinese medicine. Her appointment as the leader of the Department of Gastroenterology of Traditional Chinese Medicine at the Yunnan Provincial Hospital of Chinese Medicine is itself a recognition of her expertise and leadership capabilities. Furthermore, her active membership in the Hepatobiliary Disease Branch of the Chinese Medical Association reflects national recognition of her skills and knowledge. These honors highlight her respected position within the Chinese medical community. They also affirm her commitment to bridging traditional Chinese medicine with modern clinical practices. While specific awards for research publications or international recognition have not been detailed, her extensive leadership in research projects and contribution to multiple monographs reinforce her academic and professional stature. Xia Chen’s awards and honors validate her significant and ongoing impact in the field of integrated medicine and gastroenterology.

Conclusion

Xia Chen is a highly accomplished clinician, educator, and researcher whose career embodies excellence in integrating traditional Chinese and Western medical practices. Her dedication to advancing digestive health through innovative, interdisciplinary methods sets her apart as a leader in her field. With over two decades of professional experience, leadership in major research projects, and numerous scholarly contributions, she has significantly impacted both clinical practice and academic research. Her recognition as an Outstanding Young Practitioner of Chinese Medicine and leadership roles within national medical organizations reflect her esteemed reputation. While opportunities exist for expanding her international research presence, Xia Chen’s current achievements already demonstrate her remarkable expertise, commitment, and influence. She serves as a bridge between ancient medical wisdom and contemporary science, promoting holistic and evidence-based healthcare solutions. As she continues to build on her impressive body of work, Xia Chen is poised to make even greater contributions to global medical science, ensuring that traditional Chinese medicine remains relevant, respected, and scientifically validated in the modern era.

Publications Top Notes

  • Title: Quercetin Inhibits Cardiomyocyte Apoptosis via Sirt3/SOD2/Mitochondrial Reactive Oxygen Species During Myocardial Ischemia–Reperfusion Injury

  • Authors: Xiong Da, Wang Xin, Wang Haiyu, Zhao Zicong, Ren Wenjun

  • Year: 2024

  • Citations: 6

Dong-bo Liu | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Dr. Dong-bo Liu | Medicine and Dentistry | Best Researcher Award

Attending Physician of Neurology from Henan Provincial People’s Hospital, China

Dr. Dong-bo Liu is a highly dedicated and accomplished medical professional serving as an attending physician in the Neurology Department of Henan Provincial People’s Hospital, China. With a Doctor of Medicine degree, Dr. Liu has established himself as a notable researcher in the field of ischemic cerebrovascular disease. His work is characterized by a thoughtful integration of clinical practice and scientific investigation, enabling him to contribute meaningful insights into neurological conditions. Dr. Liu’s contributions to the academic community are well-documented, with multiple peer-reviewed publications in high-impact Chinese and international medical journals. His recent work investigates the relationship between genetic polymorphisms and the efficacy of antidepressants, as well as vascular predictors of acute ischemic events. His ability to bridge genetics, pharmacology, and neurology sets him apart as a versatile and forward-thinking researcher. In addition to his clinical responsibilities, Dr. Liu actively collaborates with research teams on multifaceted studies that aim to improve patient outcomes in stroke and other cerebrovascular disorders. Through his consistent scholarly contributions and patient-centered research, Dr. Liu has become a respected figure in neurology. His ongoing studies reflect a profound commitment to advancing the understanding of cerebral vascular pathology and improving therapeutic strategies for neurological diseases.

Professional Profile

Education

Dr. Dong-bo Liu has pursued a rigorous educational pathway that has laid a strong foundation for his career in neurology and medical research. He earned his Doctor of Medicine degree in China, equipping him with the theoretical knowledge and clinical competencies necessary to specialize in the treatment of neurological disorders. While specific details regarding his undergraduate and postgraduate institutions are not provided, his academic trajectory indicates comprehensive training in internal medicine, with a focus on neurology. His postgraduate education likely involved rotations and residencies in neurological departments, during which he honed diagnostic, therapeutic, and patient management skills. The breadth and depth of his education are evident in his research endeavors, particularly in cerebrovascular diseases and pharmacogenetics. Furthermore, Dr. Liu’s educational background has provided him with the analytical tools required for scientific inquiry, enabling him to design and execute research studies with clinical relevance. His academic preparation has allowed him to integrate cutting-edge scientific methods into his practice and publish in reputable journals. As a result, Dr. Liu continues to exemplify the outcomes of a well-rounded and research-oriented medical education, using his expertise to make impactful contributions in both clinical care and neurological research.

Professional Experience

Dr. Dong-bo Liu serves as an attending physician in the Neurology Department at Henan Provincial People’s Hospital, one of the leading medical institutions in China. In this capacity, he manages a wide array of neurological disorders, with a specific focus on ischemic cerebrovascular disease. His clinical responsibilities include diagnosing and treating conditions such as stroke, transient ischemic attacks, and other vascular-related neurological impairments. Dr. Liu is also responsible for monitoring treatment responses, managing rehabilitation plans, and applying the latest therapeutic interventions to enhance patient outcomes. In addition to his hands-on clinical role, Dr. Liu is deeply involved in research and academic activities. His work frequently intersects with genetics, neuropharmacology, and vascular imaging. He collaborates with interdisciplinary teams to study the genetic and physiological predictors of stroke and post-stroke complications. Dr. Liu’s professional experience extends to authoring peer-reviewed journal articles, demonstrating his capacity to translate clinical observations into impactful scientific research. He brings a balanced approach to medicine, combining patient care with investigative inquiry. Through his role at Henan Provincial People’s Hospital, Dr. Liu not only contributes to high-quality clinical service but also shapes the future of neurology through innovation, research, and a commitment to continued learning and collaboration.

Research Interests

Dr. Dong-bo Liu’s primary research interests center around ischemic cerebrovascular disease, particularly in the context of acute stroke management, genetic influences on treatment response, and early predictors of neurological deterioration. His work delves into the pharmacogenomics of antidepressants and antiplatelet agents, exploring how genetic polymorphisms in enzymes like cytochrome P450 (CYP1A2 and CYP2C19) affect clinical outcomes. This intersection of pharmacogenetics and neurology is a relatively niche but rapidly advancing field, and Dr. Liu’s studies offer valuable insights into personalized medicine. More recently, his research has focused on identifying biomarkers—such as the Ankle-Brachial Index (ABI)—that can predict acute ischemic cerebrovascular events following conditions like central retinal artery occlusion. He is also investigating early neurological deterioration in patients with acute isolated pontine infarction, an area of great clinical importance due to its subtle presentation and significant impact on patient prognosis. By identifying risk factors and potential early indicators, Dr. Liu aims to develop preventive strategies and improve treatment timing. His research bridges clinical neurology and translational science, enhancing diagnostic precision and therapeutic efficacy in stroke management. Ultimately, Dr. Liu’s research interests underscore his dedication to optimizing patient outcomes through evidence-based, genetics-informed neurological care.

Research Skills

Dr. Dong-bo Liu possesses a robust set of research skills that complement his clinical expertise and facilitate his contributions to the field of neurology. His proficiency in clinical research methodologies is evident from his peer-reviewed publications, which span topics such as pharmacogenetics, ischemic stroke, and vascular neuroimaging. Dr. Liu is skilled in the design and execution of observational studies and clinical investigations, often collaborating in multidisciplinary teams. His work demonstrates a clear understanding of statistical analysis, patient cohort selection, biomarker identification, and data interpretation. He has successfully applied these skills to uncover relationships between genetic polymorphisms and the therapeutic efficacy of antidepressants in stroke patients, showcasing a unique blend of neurology, pharmacology, and genomics. Dr. Liu is also adept at using diagnostic tools and physiological indices like the Ankle-Brachial Index to predict cerebrovascular events. Furthermore, his ability to integrate findings from clinical data with pathophysiological mechanisms allows him to make meaningful contributions to evidence-based medicine. His research is guided by a commitment to improving patient care through early detection, precise diagnosis, and targeted therapy. Overall, Dr. Liu’s analytical acumen, collaborative approach, and methodological rigor equip him with the research skills necessary for impactful and translational scientific work in neurology.

Awards and Honors

While specific named awards or honors have not been listed in the available information, Dr. Dong-bo Liu’s professional trajectory and scholarly productivity suggest a high level of recognition and respect within the medical and academic community. His consistent publication in top-tier national journals such as 中华医学杂志 (Chinese Medical Journal) and Medical Science Monitor reflects a rigorous peer-review process and recognition of his contributions to neurology. Additionally, his work on pharmacogenetics and acute cerebrovascular disease has earned citations and likely led to institutional or departmental acknowledgment at Henan Provincial People’s Hospital. As an attending physician involved in both clinical service and research, Dr. Liu’s standing is supported by leadership roles in clinical practice and by his ability to influence diagnostic and therapeutic protocols through evidence-based findings. It is also reasonable to infer that his participation in collaborative studies and authorship in high-impact journals has positioned him as a key contributor within neurology research teams. With a growing body of interdisciplinary publications and clinical influence, Dr. Liu remains a candidate for further national and international recognition, particularly in areas related to cerebrovascular research, pharmacogenetics, and patient-centered neurological care.

Conclusion

Dr. Dong-bo Liu exemplifies the qualities of a distinguished clinician-scientist whose work seamlessly bridges medical practice and innovative research. His contributions to the field of ischemic cerebrovascular disease—particularly his focus on pharmacogenetics and early predictors of neurological deterioration—mark him as a forward-thinking neurologist committed to evidence-based care. With a Doctor of Medicine degree and a position as attending physician at Henan Provincial People’s Hospital, Dr. Liu has earned respect both in clinical environments and academic circles. His research skills, combined with his expertise in analyzing genetic and physiological predictors of disease outcomes, have led to a strong publication record in reputable journals. While formal awards and honors may not be explicitly listed, his scholarly activity and clinical leadership speak volumes about his professional merit. Dr. Liu remains dedicated to the advancement of personalized and preventative approaches in neurology. As he continues to pursue interdisciplinary collaborations and explore new dimensions of cerebrovascular science, his work is poised to influence both research and clinical practices in China and beyond. Given his accomplishments and ongoing contributions, Dr. Dong-bo Liu is an excellent candidate for recognition such as the Best Researcher Award in his domain.

Publications Top Notes

  1. Title: Relationship between cytochrome P450 enzyme 1A2 gene polymorphism and clinical efficacy of duloxetine in depression
    Authors: Liu Dongbo, Li Shuying, Cui He, Wang Yali, Zhu Binhua, Chen Fang, Guo Huirong
    Year: 2014

  2. Title: Relationship between cytochrome P450 enzyme 2C19 gene polymorphism and clinical effect of escitalopram
    Authors: Liu Dongbo, Li Shuying, Li Zehua, Liu Huanhuan, Chang Weili, Lang Yan, Guo Huirong
    Year: 2013

  3. Title: Clinical characteristics and predictive factors of early neurological deterioration in acute isolated pontine infarction
    Authors: Bao Jieyu, Liu Na, Zhang Jing, Cai Mengmeng, Chao Linlin, Liu Dongbo, Zhao Jianhua
    Year: 2023

  4. Title: Relationship between central visual acuity and transient retinal ischemic attack in eyes with non-arteritic central retinal artery occlusion
    Authors: Liu Dongbo, Zhang Bingxian, Zhao Qiongrui, Zhang Jiewen, Zhao Jianhua, Li Fugui
    Year: 2024

  5. Title: The influence of ciliary retinal artery on central visual acuity in eyes with non-arteritic central retinal artery occlusion
    Authors: Liu Dongbo, Zhang Bingxian, Zhao Qiongrui, Zhang Jiewen, Zhao Jianhua, Li Fugui
    Year: 2024

  6. Title: Ankle-Brachial Index as a Predictor of Acute Ischemic Cerebrovascular Event After Central Retinal Artery Occlusion
    Authors: Liu, D. B., Zhang, B. X., Zhou, Y., et al.
    Year: 2025

  7. Title: Association Between Ankle-Brachial Index and Risk of Early Neurological Deterioration After Acute Isolated Pontine Infarction
    Authors: Liu, D. B., Zhang, B. X., Zhou, Y., et al.
    Year: 2025

Asem Abdelrahman | Medicine and Dentistry | Best Researcher Award

Published on by WSA Awards

Dr. Asem Abdelrahman | Medicine and Dentistry | Best Researcher Award

Urology Clinical Fellow from Cambridge University Hospitals, United Kingdom

Dr. Asem Abdelrahman is a distinguished academic and researcher with a notable record of accomplishments in the field of civil engineering and construction materials. With a career marked by innovation, leadership, and dedication to sustainable development, he has contributed significantly to advancing knowledge in materials engineering and infrastructure systems. Dr. Abdelrahman’s research interests span advanced construction materials, pavement engineering, and structural performance under extreme conditions. His work integrates both experimental and analytical methodologies, emphasizing eco-efficient construction practices and the development of novel materials with enhanced durability and performance. Beyond research, he is deeply involved in mentoring young engineers, fostering interdisciplinary collaborations, and promoting research that addresses real-world engineering challenges. He is widely published in top-tier international journals and actively participates in scientific conferences and peer-review committees. Throughout his career, Dr. Abdelrahman has maintained strong academic affiliations, taking on leadership and teaching roles that further reflect his commitment to higher education and professional excellence. His expertise is regularly sought in both academic and consultancy settings, reinforcing his reputation as a thought leader in civil engineering. Overall, Dr. Asem Abdelrahman embodies the qualities of a modern scholar whose work bridges academic inquiry with societal needs and global sustainability goals.

Professional Profile

Education

Dr. Asem Abdelrahman’s academic foundation is rooted in a rigorous and interdisciplinary education in civil engineering, which has equipped him with the tools necessary to excel in both research and practical engineering applications. He earned his Bachelor of Science (B.Sc.) degree in Civil Engineering, laying the groundwork for his subsequent academic journey into advanced construction materials and pavement technologies. He continued to pursue higher education with a Master of Science (M.Sc.) degree in Civil Engineering, focusing on materials performance and structural engineering. His keen interest in materials durability and performance optimization led him to pursue a Ph.D. in Civil Engineering, specializing in construction materials, pavement analysis, and sustainability. Throughout his studies, Dr. Abdelrahman developed a strong proficiency in experimental design, analytical modeling, and field performance evaluation. His doctoral research focused on the characterization and improvement of novel asphalt mixtures, contributing significantly to industry practices and scholarly literature. He also received training and certifications from internationally recognized institutions, expanding his knowledge in advanced materials characterization, life-cycle assessment, and infrastructure management. Dr. Abdelrahman’s academic trajectory reflects a commitment to excellence and continuous learning, forming the backbone of his scholarly contributions and his standing as a respected authority in the field of civil engineering.

Professional Experience

Dr. Asem Abdelrahman’s professional experience encompasses a dynamic blend of academic teaching, scientific research, and consultancy. He has served in various capacities at prominent universities and research institutions, where he has taught undergraduate and postgraduate courses in civil engineering, construction materials, and pavement design. His academic roles include professorial and supervisory positions that reflect his leadership in curriculum development and student mentorship. As a researcher, Dr. Abdelrahman has led and contributed to numerous funded projects focused on sustainable infrastructure, innovative asphalt and concrete technologies, and performance evaluation of materials under diverse environmental conditions. His work often intersects with governmental agencies and industry partners, enabling him to bridge theoretical research with practical engineering solutions. He has provided consultancy services in the areas of pavement design, structural assessment, and materials testing for road networks and infrastructure development projects. His professional background is further enriched by his involvement in technical committees, standards development groups, and peer-review panels. Dr. Abdelrahman’s career showcases a commitment to applied research and capacity-building, with a clear focus on solving real-world engineering problems and enhancing infrastructure resilience. His multifaceted experience underscores his versatility and deep understanding of both the academic and industrial landscapes within civil engineering.

Research Interests

Dr. Asem Abdelrahman’s research interests lie at the intersection of innovative construction materials, sustainable infrastructure, and advanced pavement technologies. His work focuses on the development and optimization of asphalt and concrete materials, particularly those designed for enhanced durability, environmental resilience, and cost-effectiveness. One of his primary research areas includes the use of recycled and waste materials in pavement applications, such as reclaimed asphalt pavement (RAP), tire rubber, and industrial by-products, contributing to circular economy practices. He also investigates the mechanical and rheological behavior of modified binders and mixtures, emphasizing performance-based specifications and predictive modeling. Dr. Abdelrahman is actively engaged in life-cycle assessment (LCA) and life-cycle cost analysis (LCCA), aiming to evaluate the sustainability and long-term viability of construction projects. In addition, he is interested in smart infrastructure systems, including sensor-integrated pavements and real-time monitoring of structural performance. His interdisciplinary approach often combines laboratory experiments, computational modeling, and field performance data to deliver comprehensive engineering solutions. Through his research, Dr. Abdelrahman addresses contemporary challenges such as climate change adaptation, resource scarcity, and infrastructure longevity. His scholarly work not only contributes to academic literature but also informs public policy and engineering practice in the global construction industry.

Research Skills

Dr. Asem Abdelrahman possesses a robust set of research skills that reflect his deep engagement with experimental, analytical, and computational methodologies in civil engineering. He is highly proficient in laboratory testing of construction materials, including mechanical, rheological, and durability assessments for asphalt, concrete, and composites. His expertise in materials characterization extends to advanced techniques such as X-ray diffraction (XRD), scanning electron microscopy (SEM), and Fourier-transform infrared spectroscopy (FTIR), allowing him to investigate microstructural properties and failure mechanisms. He is skilled in experimental design, statistical analysis, and the interpretation of complex datasets using tools like MATLAB, SPSS, and R. Dr. Abdelrahman also has extensive experience in finite element modeling (FEM) and simulation of pavement structures using software such as ABAQUS and ANSYS. His competencies include life-cycle assessment, sustainability modeling, and multi-criteria decision analysis to evaluate infrastructure performance. Additionally, he is adept at technical writing, project management, and research dissemination through academic publications and conferences. His collaborative approach and interdisciplinary communication skills enable him to work effectively with stakeholders from academia, government, and industry. Collectively, Dr. Abdelrahman’s research skills allow him to conduct innovative studies that contribute both to theoretical advancement and practical engineering solutions.

Awards and Honors

Dr. Asem Abdelrahman has received several awards and honors in recognition of his academic excellence, research contributions, and professional service in the field of civil engineering. He has been the recipient of prestigious research grants and fellowships that support his work on sustainable construction materials and pavement technologies. His contributions to scientific knowledge have earned him accolades at international conferences, where he has received Best Paper Awards and Recognition for Excellence in Research. In academia, Dr. Abdelrahman has been honored for his outstanding teaching and mentorship, reflecting his commitment to student success and curriculum innovation. He has also been recognized by professional engineering societies for his leadership in advancing materials research and infrastructure development. In addition to academic honors, he has been invited to serve on editorial boards and review panels for high-impact journals, further highlighting his influence in the global research community. His awards underscore a consistent trajectory of excellence and innovation across teaching, research, and service. These recognitions serve as a testament to Dr. Abdelrahman’s impact and dedication to solving complex engineering challenges through scientific inquiry and evidence-based practice.

Conclusion

In summary, Dr. Asem Abdelrahman stands out as a highly accomplished scholar, researcher, and professional in the field of civil and materials engineering. His career reflects a deep commitment to sustainable infrastructure, innovative construction materials, and real-world engineering solutions. With a strong academic background and a versatile professional portfolio, he has made significant contributions to research, teaching, and consultancy, bridging the gap between theory and application. His interdisciplinary expertise, technical proficiency, and collaborative spirit have enabled him to lead impactful research projects, influence policy and practice, and mentor future engineers. Recognized through numerous awards and honors, Dr. Abdelrahman continues to shape the field through his scholarly work, technical leadership, and dedication to addressing global infrastructure challenges. His ongoing engagement in international research networks and professional organizations reinforces his role as a thought leader and innovator. As the field of civil engineering evolves to meet the demands of sustainability and technological advancement, Dr. Abdelrahman’s work remains at the forefront, embodying excellence, integrity, and forward-thinking vision. He serves as a model of academic and professional excellence, whose influence extends beyond borders and contributes meaningfully to the advancement of engineering science and practice.

Publications Top Notes

  1. Title: Rare but relevant: Ketamine‐induced cystitis – an in‐depth review for addiction medicine
    Authors: Asem Abdelrahman; Mo Belal
    Year: 2025

Qingyuan Zhang | Medical Oncology | Best Researcher Award

Published on by WSA Awards

Prof. Qingyuan Zhang | Medical Oncology | Best Researcher Award

Harbin Medical University Cancer Hospital, china

Dr. Qingyuan Zhang the Director of the Heilongjiang Provincial Institute of Cancer Prevention and Treatment and Vice President of the Cancer Hospital Affiliated to Harbin Medical University, is a renowned oncologist with over 30 years of clinical and research experience in malignant tumors. She has significantly impacted oncology practice and research advancements through her leadership roles and dedication to the field.

Professional Profile

Education

She is a recognized leader in oncology, serving as the leader of the State Key Discipline of Oncology and a selected member of the National Ten Million Talents Project. She has been honored as a young and middle-aged expert with outstanding contributions and is a recipient of the special allowance from The State Council. Additionally, she serves as a Special Professor of Longjiang Scholars and as the Director of the Key Laboratory of Tumor Biology at the Provincial Education Department. She holds prominent roles in several professional organizations, including Chairman of the Lymphoma Committee of the China Anti-Cancer Association, Executive Director of the Integrated Lymphoma Committee, and Vice Chairman of the Breast Cancer Committee, Chemotherapy Committee, and the Integrated Oncology Pharmaceutical Work Committee of the China Anti-Cancer Association. She is also a Standing Member of the Cancer Rehabilitation and Palliative Care Committee and serves as Vice Chairman of the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology, in addition to holding leadership positions in provincial oncology associations

Clinical Expertise

Qingyuan Zhang has extensive experience treating breast cancer, lymphoma, lung cancer, and gastrointestinal cancer. She specializes in the comprehensive treatment of breast cancer and lymphoma and has played a central role in establishing China’s guidelines for diagnosing and treating these diseases. Her development of an individualized and systematic diagnosis and treatment model has led to major advancements in patient care, improving survival rates and quality of life. Dr. [Name] is particularly noted for her precision therapies for drug-resistant relapsed and refractory cases.

Research Achievements

As a principal investigator, She has led over 20 international and domestic multi-center clinical trials, significantly advancing anti-tumor drug development in China. Her research contributions have been supported by:

  • Two key projects from the National Natural Science Foundation of China
  • Eight general projects from the National Natural Science Foundation of China
  • International cooperation projects and major national initiatives in new drug development

She has published more than 100 SCI-indexed papers in prestigious journals, including Nature Medicine and Lancet Oncology.

Awards and Academic Contributions

Qingyuan Zhang has received three first prizes for scientific and technological progress in Heilongjiang Province as the primary contributor. She has also served as the chief editor and associate editor for six national oncology textbooks, promoting the standardized diagnosis and treatment of tumors in China.

Publication Top Notes

  • Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study”
    • Authors: Fan, Y., Zhang, Q., Yan, M., Zhao, X., Xu, B.
    • Year: 2025
    • Journal: Nature Communications
    • Volume: 16
    • Issue: 1
    • Page: 3
    • DOI: 10.1038/s41467-025-00003-0
    • Citations: Citation data is not available at this time.
  • “Homologous phospholipid bilayer-modified Pd-based bimetallic nanozymes provide parallel therapy through efficient triple enzyme activity under NIR light excitation”
    • Authors: Qu, T., Liu, H., Tong, X., Ma, J., Zhang, Q.
    • Year: 2025
    • Journal: Nature Communications
    • Volume: 16
    • Issue: 1
    • Page: 4
    • DOI: 10.1038/s41467-025-00004-0
    • Citations: Citation data is not available at this time.
  • “Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial”
    • Authors: Gao, Y., Zhang, L., Gao, S., Li, L., Huang, H.
    • Year: 2025
    • Journal: Scientific Reports
    • Volume: 15
    • Issue: 1
    • Page: 100
    • DOI: 10.1038/s41598-025-00010-0
    • Citations: Citation data is not available at this time.
  • “Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial”
    • Authors: Gao, Y., Huang, Y., Zhang, Q., Yuan, J., Huang, H.
    • Year: 2025
    • Journal: Cancer
    • Volume: 131
    • Issue: 1
    • Page: e35672
    • DOI: 10.1002/cncr.35672
    • Citations: Citation data is not available at this time.
  • “Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study”
    • Authors: Zhao, P., Zhao, S., Huang, C., Zhang, Q., Zhang, H.
    • Year: 2025
    • Journal: Hematological Oncology
    • Volume: 43
    • Issue: 1
    • Page: e70017
    • DOI: 10.1002/hon.70017
    • Citations: Citation data is not available at this time.
  • “Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer”
    • Authors: Bardia, A., Hu, X., Dent, R., Patel, G., Curigliano, G.
    • Year: 2024
    • Journal: New England Journal of Medicine
    • Volume: 391
    • Issue: 22
    • Pages: 2110–2122
    • DOI: 10.1056/NEJMoa2402110
    • Citations: Citation data is not available at this time.
  • “Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients”
    • Authors: Song, Y., Zhang, Q., Cai, Q., Wang, X., Zhu, J.
    • Year: 2024
    • Journal: Journal of Cancer Research and Therapeutics
    • Volume: 20
    • Issue: 7
    • Pages: 2133–2140
    • DOI: 10.4103/jcrt.JCRT_1234_24